重组人血管内皮抑素联合卡铂方案对非小细胞肺癌术后近期疗效及血标志物的影响  

rh-endostafin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer

作　　者：齐大亮[1] 杨彦卓[1] 刘竹君[2] 王庆生[3] 辛亮[1] 崔焱[1] 乔宇峰[1] 冯奎 

机构地区：[1]天津市肿瘤防治重点实验室天津医科大学附属肿瘤医院高级病房,300060 [2]天津市肿瘤防治重点实验室天津医科大学附属肿瘤医院肺部肿瘤内科,300060 [3]天津市肿瘤防治重点实验室天津医科大学附属肿瘤医院预防医学科,300060 [4]河北省沧州市南大港医院胸科

出　　处：《中华医学杂志》2009年第15期1057-1059,共3页National Medical Journal of China

摘　　要：目的探讨重组人血管内皮抑素（恩度，Endostar^TM）联合多西紫杉醇和卡铂（TP）方案术后辅助治疗非小细胞肺癌（NSCLC）的疗效及对外周血标志物的影响。方法采用重组人血管内皮抑素联合TP方案（治疗组）和单用TP方案（对照组）治疗Ⅰb-Ⅲa期的NSCLC术后患者各18例，观察近期疗效、并检测治疗前后外周血循环血管内皮细胞（CEC）数量及肿瘤标志物CEA、NSE、CYFR21-1的水平。结果外周血CEC及CEA、NSE、CYFR21—1治疗后均有下降，第4周期治疗后治疗组的CEC和NSE与对照组比较差异有统计学意义（P=0．016和P=0．013）。治疗组无病生存时间延长，但尚无统计学意义。复发、转移患者CEC明显升高，经治疗病情好转后下降。结论重组人血管内皮抑素联合TP方案术后辅助治疗NSCLC较单纯化疗显示近期疗效上的优势、长期生存结果值得期待。CEC可能是一个较好的预测疗效的指标。Objective To evaluate the efficacy of EndostarTM （rh-endostatin, YH-16） combined with docetaxel and carboplatin （TP）regimen for the adjuvant treatment of non-small lung cancer （NSCLC） and its impact on circulating blood markers. Methods 36 patients with stage Ⅰb-Ⅲ a postoperative NSCLC, were randomly divided into the treatment group, EndostarTM plus TP regimen, and the control group, TP regimen only, respectively. DFS and toxicities of patients were observed. The numbers of CEC and the levels of tumor marker CEA, NSE and CYFR21-1 were measured. Results The numbers of CEC and the levels of CEA, NSE and CYFR21-1 decreased after treatment. There were significant differences in CEC and NSE between treatment group and control group after four cycles of treatment, respectively （P = 0. 016 and 0. 013）. Disease-free survival time （DFS） was longer in treatment group than control group but without significant difference. CEC was significantly increased in recurrent and metastasis cases and decreased after effective treatment. Conclusion EndostarTM combined with TP regimen seem to be superior to TP alone in some short term index for the treatment of postoperative NSCLC even though long-term survival is still anticipated. CEC, as a biomarker, may be useful in predicting the efficacy of the such synergistic treatment.

关 键 词：癌 非小细胞肺 卡铂 药物疗法 联合 重组人血管内皮抑素 

分 类 号：R686[医药卫生—骨科学]